. "Maturity-onset diabetes of the young 3 (MODY 3)" . "11120" . "484441" . "Brunerov\u00E1, Ludmila" . "Pr\u016Fhov\u00E1, \u0160t\u011Bp\u00E1nka" . . "5"^^ . . "5"^^ . "Maturity-onset diabetes of the young 3 (MODY 3)"@en . . . "9" . "2" . "Diabetologie, metabolismus, endokrinologie, v\u00FD\u017Eiva" . "CZ - \u010Cesk\u00E1 republika" . "P(NB7420), Z(MSM0021620814)" . . "MODY 3 belongs to the monogennic forms of diabetes. It is caused by the mutation of gene for transcription factor HNF-1 alpha, localized on the chromosome 12. It is characterized by the discrepancy between impaired insulin response to glucose and well-preserved insulin response to sulphonylurea derivates. The theoretical presumption of sulphonylurea hypersensitivity is well-preserved insulin sensitivity in MODY 3 patients and probably prolonged clearence of sulphonylureas. MODY 3 is typically manifested in young nonobese people by osmotic symptoms resulting from hyperglycaemia, without ketoacidosis and by the rapid development of chronic microvascular complications. Insulin treatment had been the only one therapeutical modality in the young MODY 3 patients till nowadays, but recently the safety and efficacy of the longterm sulphonylurea treatment has been reported."@en . . "Maturity-onset diabetes of the young 3 (MODY 3)"@cs . . "And\u011Bl, Michal" . . . "RIV/00216208:11120/06:00001649!RIV10-MSM-11120___" . . . "1211-9326" . . . . . . "MODY 3 pat\u0159\u00ED mezi monogenn\u00ED (autozom\u00E1ln\u011B dominantn\u00ED) formy diabetu a je zp\u016Fsoben\u00FD mutac\u00ED genu pro transkrip\u010Dn\u00ED faktor HNF-1 alfa, lokalizovan\u00FD na dlouh\u00E9m ram\u00E9nku 12. chromozomu. MODY 3 je charakterizov\u00E1n diskrepanc\u00ED mezi poru\u0161enou inzulinovou odpov\u011Bd\u00ED na stimulaci gluk\u00F3zou, ale dob\u0159e zachovalou sekrec\u00ED inzulinu po pod\u00E1n\u00ED deriv\u00E1t\u016F sulfonylurey. P\u0159edpokladem v\u00FDborn\u00E9 \u00FA\u010Dinnosti deriv\u00E1t\u016F sulfonylurey u pacient\u016F s MODY 3 je zachoval\u00E1 inzulinov\u00E1 senzitivita a pravd\u011Bpodobn\u011B sn\u00ED\u017Een\u00E1 clearance sulfonylureov\u00FDch deriv\u00E1t\u016F. Klinicky se MODY 3 projevuje u mlad\u00FDch a \u0161t\u00EDhl\u00FDch osob osmotick\u00FDmi p\u0159\u00EDznaky z hyperglykemie bez ketoacid\u00F3zy. Typick\u00E1 je rychl\u00E1 progrese mikrovaskul\u00E1rn\u00EDch komplikac\u00ED. Terapeuticky se dosud u mlad\u00FDch MODY 3 diabetik\u016F uplat\u0148oval inzulin, nov\u011B je dokumentovan\u00E1 \u00FA\u010Dinnost a bezpe\u010Dnost l\u00E9\u010Dby deriv\u00E1ty sulfonylurey" . "[B6586F624696]" . . "Clinical symptoms; Epidemiology; MODY 3; Pathophysiology; Therapy"@en . . "Maturity-onset diabetes of the young 3 (MODY 3)"@en . "RIV/00216208:11120/06:00001649" . . "MODY 3 pat\u0159\u00ED mezi monogenn\u00ED (autozom\u00E1ln\u011B dominantn\u00ED) formy diabetu a je zp\u016Fsoben\u00FD mutac\u00ED genu pro transkrip\u010Dn\u00ED faktor HNF-1 alfa, lokalizovan\u00FD na dlouh\u00E9m ram\u00E9nku 12. chromozomu. MODY 3 je charakterizov\u00E1n diskrepanc\u00ED mezi poru\u0161enou inzulinovou odpov\u011Bd\u00ED na stimulaci gluk\u00F3zou, ale dob\u0159e zachovalou sekrec\u00ED inzulinu po pod\u00E1n\u00ED deriv\u00E1t\u016F sulfonylurey. P\u0159edpokladem v\u00FDborn\u00E9 \u00FA\u010Dinnosti deriv\u00E1t\u016F sulfonylurey u pacient\u016F s MODY 3 je zachoval\u00E1 inzulinov\u00E1 senzitivita a pravd\u011Bpodobn\u011B sn\u00ED\u017Een\u00E1 clearance sulfonylureov\u00FDch deriv\u00E1t\u016F. Klinicky se MODY 3 projevuje u mlad\u00FDch a \u0161t\u00EDhl\u00FDch osob osmotick\u00FDmi p\u0159\u00EDznaky z hyperglykemie bez ketoacid\u00F3zy. Typick\u00E1 je rychl\u00E1 progrese mikrovaskul\u00E1rn\u00EDch komplikac\u00ED. Terapeuticky se dosud u mlad\u00FDch MODY 3 diabetik\u016F uplat\u0148oval inzulin, nov\u011B je dokumentovan\u00E1 \u00FA\u010Dinnost a bezpe\u010Dnost l\u00E9\u010Dby deriv\u00E1ty sulfonylurey"@cs . . "Bro\u017E, Jan" . "Lebl, Jan" . "Maturity-onset diabetes of the young 3 (MODY 3)" . . "5"^^ . . "Maturity-onset diabetes of the young 3 (MODY 3)"@cs .